Cancer du sein HER2-low : comment un concept biologique s’immisce-t-il dans la décision thérapeutique ?: HER2-low breast cancer: how does a biological concept interfere in therapeutic decision?

Abstract

The emergence of a new tumor entity called HER2-low breast cancer leads us to reconsider therapeutic indications in patients whose tumors were usually considered as luminal or triple negative. The development of antibody-drug conjugates (ADCs) allows using HER2 as a vector of a cytoxic drug with significant clinical efficacy in breast cancer with low HER2 expression. Trastuzumab deruxtecan monotherapy is currently evaluated in phase III trials in HER2-low patients, but also in combination in earlier phase studies. Many ADCs are in development, with highly anticipated results. The toxicities of these various ADCs seem manageable and compatible with prolonged administration. Her2-low breast cancer subtype may benefit from dedicated therapeutic strategies in the next few years.

Keywords: Breast cancer HER2-low Antibody drug conjugate; Cancer du sein HER2-low Conjugué anticorps drogue.